Key Insights

Highlights

Success Rate

84% trial completion

Published Results

79 trials with published results (17%)

Research Maturity

241 completed trials (53% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

10.3%

47 terminated out of 455 trials

Success Rate

83.7%

-2.8% vs benchmark

Late-Stage Pipeline

14%

62 trials in Phase 3/4

Results Transparency

33%

79 of 241 completed with results

Key Signals

79 with results84% success47 terminated

Data Visualizations

Phase Distribution

271Total
Not Applicable (63)
Early P 1 (2)
P 1 (60)
P 2 (84)
P 3 (47)
P 4 (15)

Trial Status

Completed241
Unknown113
Terminated47
Withdrawn29
Active Not Recruiting14
Recruiting5

Trial Success Rate

83.7%

Benchmark: 86.5%

Based on 241 completed trials

Clinical Trials (455)

Showing 20 of 20 trials
NCT05728970CompletedPrimary

POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.

NCT04354558Active Not Recruiting

French Single Centre Experience of Critically Ill Patients With Covid 19

NCT04337424CompletedPrimary

Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2

NCT05787444CompletedPrimary

Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test

NCT06684379Phase 1RecruitingPrimary

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

NCT04353609CompletedPrimary

Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases

NCT04362267WithdrawnPrimary

Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital

NCT04336215Completed

Rutgers COVID-19 Cohort Study

NCT04356495Phase 2Completed

Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation

NCT07266558Phase 4Active Not RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

NCT04967807Not ApplicableActive Not Recruiting

Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study)

NCT05032976Active Not Recruiting

Korea Comirnaty Post-marketing Surveillance

NCT04378842CompletedPrimary

COVID-19 and ICU-acquired MDR Bacteria

NCT05954286Phase 2CompletedPrimary

PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

NCT06333704Active Not RecruitingPrimary

Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE

NCT04466683Phase 2Active Not Recruiting

Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia

NCT04363853Phase 2Active Not RecruitingPrimary

Tocilizumab Treatment in Patients With COVID-19

NCT04703114Not ApplicableCompleted

Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV)

NCT06585241Phase 4RecruitingPrimary

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

NCT04649021Phase 2CompletedPrimary

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population

Scroll to load more

Research Network

Activity Timeline